Drug Trial Radar · NCT00224874
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Sep 2005
Primary completion
Jan 2009
Study completion Jun 2012
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- Collaborators
- National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
- First posted
- Sep 23, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.
Conditions
- Graft vs Host Disease
- Immune System Disorders
Interventions
EtanerceptDrug
Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
Mycophenolate MofetilDrug
Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
Denileukin DiftitoxDrug
Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
PentostatinDrug
Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Complete Response (CR) at Day 28 of TherapyTime frame: Measured at Day 28
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California
San Diego, California
Stanford Hospital and Clinics
Stanford, California
University of Florida College of Medicine (Shands)
Gainesville, Florida
Johns Hopkins/SKCCC
Baltimore, Maryland
DFCI/Brigham & Women's Hospital
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Washington University/Barnes Jewish Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke University Medical Center (Peds)
Durham, North Carolina
University Hospitals of Cleveland/Case Western
Cleveland, Ohio
Oregon Health Sciences University
Portland, Oregon
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
University of Texas/MD Anderson CRC
Houston, Texas
Texas Transplant Institute
San Antonio, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.